Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2A Trial of ENB 003 in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

NCT04205227 is registered in ClinicalTrials.gov with ENB Therapeutics, Inc as lead sponsor.

NCT NCT04205227
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04205227 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2A Trial of ENB 003 in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Lead sponsor
ENB Therapeutics, Inc
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
February 18, 2020
Completion date
March 31, 2026
Enrollment
137 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, melanoma, ovary cancer, pancreatic cancer, solid tumor